NASDAQ:STOK - Stoke Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $44.38
  • Forecasted Upside: -6.24 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$47.33
▲ +1.18 (2.56%)
1 month | 3 months | 12 months
Get New Stoke Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STOK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STOK

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$44.38
▼ -6.24% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for Stoke Therapeutics in the last 3 months. The average price target is $44.38, with a high forecast of $68.00 and a low forecast of $30.00. The average price target represents a -6.24% upside from the last price of $47.33.
Buy
The current consensus among 9 contributing investment analysts is to buy stock in Stoke Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/1/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/30/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/28/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/28/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/26/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/24/2020

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/13/2020Canaccord GenuityBoost Price TargetBuy$49.00 ➝ $53.00High
i
Rating by Michelle Gilson at Canaccord Genuity
11/13/2020BTIG ResearchBoost Price TargetBuy$46.00 ➝ $68.00High
i
11/13/2020Credit Suisse GroupBoost Price TargetOutperform$42.00 ➝ $49.00Medium
i
10/23/2020Cantor FitzgeraldInitiated CoverageOverweight$49.00High
i
Rating by A. Young at Cantor Fitzgerald
9/29/2020Needham & Company LLCInitiated CoverageBuy$42.00Low
i
9/29/2020JPMorgan Chase & Co.Initiated CoverageNeutralLow
i
8/11/2020HC WainwrightReiterated RatingBuy$30.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
7/9/2020Canaccord GenuityReiterated RatingBuy$44.00High
i
Rating by Michelle Gilson at Canaccord Genuity
6/26/2020Canaccord GenuityReiterated RatingBuy$44.00High
i
Rating by Michelle Gilson at Canaccord Genuity
5/18/2020HC WainwrightReiterated RatingBuy$30.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
3/23/2020CowenReiterated RatingBuyLow
i
12/17/2019WedbushInitiated CoverageOutperform$31.00Medium
i
Rating by L. Chico at Wedbush
12/9/2019HC WainwrightReiterated RatingBuy$30.00High
i
Rating by D. Chattopadhyay at HC Wainwright
12/3/2019JPMorgan Chase & Co.Lower Price TargetOverweight$34.00 ➝ $33.00High
i
Rating by Jessica Fye at JPMorgan Chase & Co.
11/12/2019BTIG ResearchInitiated CoverageBuy$46.00High
i
10/25/2019HC WainwrightInitiated CoverageBuy$30.00High
i
Rating by D. Chattopadhyay at HC Wainwright
8/15/2019CowenReiterated RatingBuyLow
i
Rating by Yaron Werber at Cowen Inc
7/15/2019Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$35.00Medium
i
7/15/2019Canaccord GenuityInitiated CoverageBuy ➝ Buy$44.00Medium
i
7/15/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$34.00Medium
i
7/15/2019CowenInitiated CoverageOutperform ➝ OutperformMedium
i
(Data available from 11/25/2015 forward)
Stoke Therapeutics logo
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.
Read More

Today's Range

Now: $47.33
$46.21
$49.00

50 Day Range

MA: $40.56
$35.36
$46.57

52 Week Range

Now: $47.33
$15.82
$49.01

Volume

159,488 shs

Average Volume

152,717 shs

Market Capitalization

$1.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.23